

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 730 406 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
08.07.1998 Bulletin 1998/28

(21) Application number: 95900207.2

(22) Date of filing: 07.11.1994

(51) Int. Cl.⁶: **A01N 25/28**, **A01N 43/70**,
A01N 41/10
// (**A01N43/70**, 37:26, 25:28),
(**A01N41/10**, 25:28)

(86) International application number:
PCT/GB94/02440

(87) International publication number:
WO 95/13698 (26.05.1995 Gazette 1995/22)

(54) MICROCAPSULES CONTAINING SUSPENSIONS OF BIOLOGICALLY ACTIVE COMPOUNDS

**MIKROKAPSELN, DIE SUSPENSIONEN VON BIOLOGISCH AKTIVEN VERBINDUNGEN
ENTHALTEN**

**MICROCAPSULES CONTENANT DES SUSPENSIONS DE COMPOSES BIOLOGIQUEMENT
ACTIFS**

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GRIE IT LI LU MC NL
PT SE**

(30) Priority: 15.11.1993 US 153111

(43) Date of publication of application:
11.09.1996 Bulletin 1996/37

(73) Proprietor: **ZENECA LIMITED**
London W1Y 6LN (GB)

(72) Inventors:
• **SCHER, Herbert, Benson**
Moraga, CA 94556 (US)
• **CHEN, Jin, Ling**
El Cerrito, CA 94530 (US)

(74) Representative:
Waterman, John Richard et al
Intellectual Property Department,
ZENECA Agrochemicals,
Jealott's Hill Research Station,
P.O. Box 3538
Bracknell, Berkshire RG42 6YA (GB)

(56) References cited:

EP-A- 0 252 897	EP-A- 0 270 742
EP-A- 0 281 521	WO-A-91/12884
WO-A-92/10285	GB-A- 929 402
GB-A- 2 011 341	US-A- 2 800 458
US-A- 4 285 720	US-A- 4 722 838
US-A- 4 956 129	

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 730 406 B1

DescriptionField of the Invention

5 This invention relates to microencapsules which contain a solid biologically active compound suspended in a liquid, and processes for their preparation and for the use of such microcapsules.

Background and Prior Art

10 Microcapsule technology has been in existence for a number of years. Microcapsules have a variety of uses, especially for containing dyes, inks, chemical reagents, pharmaceuticals, flavoring materials, and more especially agrochemicals, that is fungicides, bactericides, insecticides, herbicides and the like.

The development and uses of microencapsulation are described by Gordon Marrs and Herbert B. Scher in Chapter 4 of "Controlled Delivery of Crop Protection Agents" (London, Taylor and Francis, 1990). As discussed by Marrs and
15 Scher, there are three methods of forming microcapsules: i) physical methods, ii) phase separation methods and iii) interfacial polymerization.

In the third of these methods, the walls of microcapsules are generally formed of polymeric material produced by a polymerisation reaction which preferably takes place at the interface between two phases, usually an aqueous phase and a water-immiscible organic phase. Thus, they may be produced from a water-in-oil emulsion or more usually an oil-
20 in-water emulsion.

A basic patent dealing with microcapsule technology is U.S. Patent No. 4,285,720. In this patent the walls of the microcapsules are produced from polymers formed by reactions of isocyanate monomers.

A second means of forming microcapsules by interfacial polymerization is described in U.S. Patent 4,956,129. In this patent polymeric microcapsule walls are produced from etherified urea-formaldehyde prepolymers which undergo
25 self-condensation polymerization under acid conditions.

Various improvements on these techniques have been suggested. For example, U.S. Patent 4,140,516, describes the use of phase transfer catalysts while U.S. Patent 4,448,929, describes the use of an improved protective colloid. However, in all these patents, the process have been applied only to liquids, i.e., to materials which are liquid at ambient temperature or to solutions. Unfortunately, many biologically active compounds are solids with high melting points and
30 are not readily soluble in most commonly used solvents. The benefits of microencapsulation e.g., controlled release and increased longevity of efficacy have not been readily available to such compounds using known techniques.

It is also known to surround solids by a polymer matrix. Thus, in U.S. Patent 4,428,983, there is described a process for producing quartz crystals in a polymer matrix. The patent uses the term suspension for describing the paste of quartz crystals in the prepolymer, but this publication does not describe the production of microcapsules containing a
35 solid suspended in a liquid.

There are a large number of publications dealing with the production and application of microencapsulated formulations of haloacetanilide herbicides. These include U.S. Patents 4,280,833; 4,417,916; 4,534,783; 4,563,212; and 4,640,709. Additionally, U.S. Patent 4,936,901 discloses herbicidal compositions which are dry flowable water-dispersible granular formulations comprising a mixture of microcapsules of a water-insoluble pesticide (including a haloacetanilide herbicide) encapsulated within a polymeric shell wall and at least one other pesticide which is nonencapsulated. Such compositions were necessary since no satisfactory techniques to produce a microcapsule containing a solid, biologically activate herbicide suspended in a liquid have been known.

GB-A-2011341 discloses an encapsulation technique using interfacial polymerization which may be applied to solids suspended in liquids. It is not surprising that capsules containing a biologically active solid suspended in a liquid have not been made up until the present time since the problems to be faced in producing such a capsule are formidable. For example, in forming such capsules from an oil-in-water emulsion, the following difficulties must be addressed:

Firstly, a stable suspension of the solid in a water-immiscible liquid must be produced. If dispersants or surfactants are used, they must not interfere with further processes of dispersion used in making microcapsules.

Secondly, the suspension must be dispersed in water to produce stable, well dispersed droplets. For biologically
50 active substances, it is preferable to have very small droplets of liquid dispersed in water to present a high surface area in the resulting microcapsules. To produce very small droplets requires high shear forces which would tend to break down the droplets and/or release the solid from suspension. Surfactants are usually required to achieve good dispersion and stable droplets.

Thirdly, the presence of one or more surfactants can make the dispersed droplet system unstable and the phenomenon of phase inversion may occur i.e., the water forms small droplets within the liquid, a water-in-oil emulsion.

Fourthly, the solid suspended in the water-immiscible liquid is liable to migrate to the aqueous phase, particularly when emulsifying surfactants are used.

SUMMARY OF THE INVENTION

It has now been found that the above problems can be overcome and it is possible to produce microcapsulated compositions containing a solid biologically active compound suspended in a liquid.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the invention, a microencapsulated formulation of a solid biologically active compound suspended in a liquid is produced by phase separation or interfacial polymerization techniques. The preferred technique is interfacial polymerization, especially producing the capsules from an oil-in-water emulsion by procedures such as those described in U.S. Patent 4,285,720, and U.S. Patent 4,956,129, modified as described herein.

The solid, biologically active compound is preferably an agrochemical and especially a herbicide.

Preferred herbicides are s-triazines, e.g., atrazine, simazine, propazine, cyprozone;

Sulphonylureas e.g., chlorsulfuron, chlorimuronethyl, metsulfuron-methyl, thiameturon-methyl; and

Triketones e.g., sulcotrione.

An especially preferred herbicide is atrazine.

Another suitable compound is the fungicide (E)-methyl 2-[2-(6-(2-cyanophenoxy)pyrimidin-4-yloxy)phenyl]-3-methoxypropenoate.

The liquid in which the solid is suspended may suitably be a second herbicide, especially a thiocarbamate or a haloacetanilide and preferably acetochlor.

The haloacetanilides, particularly the subclass generally known as α -chloroacetanilides, are a well-known class of herbicidal agents and have been used and proposed for use in a number of crop and non-crop applications. Some of the better known members of this class include α -chloro-6'-ethyl-N-(2-methoxy-1-methylethyl)-acetanilide (metolachlor), N-butoxymethyl- α -chloro-2',6'-diethylacetanilide (butachlor), α -chloro-2',6'-diethyl-N-methoxymethylacetanilide (alachlor), 2-chloro-N-(ethoxymethyl)-6'-ethyl-o-acetotoluidide (acetochlor) and α -chloro-N-isopropylacetanilide (propachlor). Many other compounds of this type are disclosed in numerous patents.

The thiocarbamates are a well known class of herbicide which includes

Molinate - S-ethyl hexahydro-1H-azepine-1-carbothioate

Butylate - S-ethyl diisobutylthiocarbamate

EPTC - ethyl dipropylthiolcarbamate

Triallate - 2,3,3-trichloroallyl-diisopropylthiolcarbamate

Diallate - cis-1-trans-2,3-dichloroallyl-diisopropylthiolcarbamate

Vernolate - S-propyl dipropylthiolcarbamate

The microcapsules of the invention suitably contain 0.1-55% by weight of biologically active compounds.

The liquid may alternatively be any organic solvent which is immiscible with water, does not dissolve the biologically active solid to appreciable extent and is polar enough to dissolve the prepolymers used to form the walls of the microcapsules.

Suitable examples of such solvents are aromatic compounds such as xylenes or naphthalenes, especially Solvesso 200; aliphatic compound such as alkyl esters, especially alkyl acetates, e.g., Exxate 700 - Exxate 1000; alkyl phthalates, such as diethyl phthalate, dibutylphthalate; alcohols, such as isopropyl alcohol; ketones, such as acetophenone, cyclohexanone. The solvent may be a mixture of more than one compound.

A safener for either herbicide may be present and many such safeners or antidotes as well known in the art. Preferred types for use with haloacetanilide herbicides include dichloroacetamides such as dichlormid (N,N-diallyl dichloroacetamide); 2,2,5-trimethyl-3-dichloroacetyl oxazolidine (R-29148), N-dichloroacetyl-1-oxa-4-azaspiro[4,5]decane (AD-67); 4-dichloroacetyl-2,3-dihydro-3-methyl-1,4-benzoxazine (CGA-154281); 1-(dichloroacetyl)hexahydro-3,3,8a-trimethylpyrrolo-[1,2-a]-pyrimidin-6(2H)-one and N-(1,3-dioxolan-2-yl-methyl)-N-(2-propenyl)-2,2-dichloroacetamide (PPG-1292).

These and other dichloroacetamides are described, for instance, in U.S. Patents 4,124,372; 4,256,481; 4,294,764; 4,448,960; 4,601,745; 4,618,361; 4,708,735 and 4,900,350. Additional known types of safeners or antidotes include certain oxime derivatives (U.S. Patents 4,070,389 and 4,269,775, for instance), thiazole carboxylic acids and derivatives (U.S. Patent 4,199,506 for instance), haloacyltetrahydroisoquinolines (U.S. Patent 4,755,218, for example), aryl cyclopropane carbonitriles (U.S. Patent 4,859,232, for example) and 1,8-naphthalic acid, its anhydride and derivatives.

Safeners or antidotes, when included, will usually be contained in the organic or water-immiscible phase.

The preferred materials for the microcapsule is a polyurea, formed as described in U.S. Patent 4,285,720, or a urea-formaldehyde polymer as described in U.S. Patent 4,956,129. The polyurea is especially preferred.

In brief, the process comprises the following steps.

Step 1. Producing the solid biologically active material with the required particle size, suitably by a milling process. The preferred average particle size of the solid is 0.01-50 microns, preferably 1-10 microns and even more preferably 1-5 microns.

Step 2. Suspending the solid biologically active material in an organic liquid. The liquid is preferably a poor solvent for the solid, that is it will not dissolve large quantities of the solid. The liquid must also be immiscible with water, but polar enough to dissolve the prepolymers used in the microencapsulation process.

The liquid preferably contains a dispersant capable of keeping the solid in the liquid but which does not allow the solid to be extracted into the water when the suspension is dispersed into water. In addition, when the suspension is added to water, the dispersant must not allow phase inversion to occur i.e., the water must not be allowed to be taken into an emulsion by the organic liquid.

The exact choice of dispersants will depend on the choice of solid and the liquid but preferred dispersants are non-ionic surfactants which act by steric hindrance and are active only at the solid/organic liquid interface and do not act as emulsifying agents. Such dispersants are suitably made up of i) a polymeric chain having a strong affinity for the liquid and ii) a group which will absorb strongly to the solid.

Examples of such dispersants are Hypermer PS1, Hypermer PS2, Hypermer PS3 and Hypermer LP2; Atlox LP1, Atlox LP2, Atlox LP4, Atlox LP5, Atlox LP6, Atlox PS2 and Atlox PS3 available from ICI Americas Inc., Wilmington, Delaware; and Agrimer polymers from GAF, e.g., Agrimer AL-220, Agrimer AL-216.

In general, the range of dispersant concentration used is from about 0.01 to about 10% by weight based on the organic phase, but higher concentration of surfactant may also be used.

Alternatively, the procedures of Steps 1 and 2 may be varied by performing a milling process, to reduce the particle size of the solid, after the solid biologically active material is suspended in the organic liquid (media milling).

Step 3: A physical dispersion of a water-immiscible phase in an aqueous phase is prepared. To obtain the appropriate dispersion, the organic phase is added to the aqueous phase, with stirring. A suitable dispersing means is employed to disperse the organic phase in the liquid phase. The means may be any high shear device, so as to obtain a desired droplet (and corresponding microcapsule particle) size within the range of from about 1 to about 200 microns. Preferably the droplet size is from about 1 to about 30 microns, most preferably from about 3 to about 20 microns, average. Once the proper droplet size is obtained, the dispersion means is discontinued. Only mild agitation is required for the remainder of the process. The water-immiscible phase comprises the solid, biologically active compound suspended in the liquid to be encapsulated prepared as described above in Steps 1 and 2. The aqueous phase is comprised of water and a material termed a "protective colloid". Preferably it further contains a surfactant.

In general, the surfactant or surfactants in this phase may be anionic or non-ionic surfactants with an HLB range of from about 12 to about 16 that is high enough to form a stable oil-in-water emulsion. If more than one surfactant is used, the individual surfactants may have values lower than 12 or higher than 16. However, when combined together the overall HLB value of the surfactants will be in the range 12-16. Suitable surfactants include polyethylene glycol ethers of linear alcohols, ethoxylated nonylphenols, naphthalene sulfonates, and the like. Other suitable surfactants include block copolymers of propylene oxide and ethylene oxide and anionic/nonionic blends. Preferably the hydrophobic portion of the surfactant has chemical characteristics similar to the organic liquid. Thus, when the organic liquid is an aromatic solvent, the surfactant would suitably be an ethoxylated nonphenylphenol.

Especially preferred surfactants are Tergitol NP7, Tergitol NP40 and Tergitol 15-S-20.

In general, the range of surfactant concentration in the process is from about 0.01 to about 10.0 percent by weight, based on the aqueous phase, but higher concentrations of surfactant may also be used.

The protective colloid present in the aqueous (or continuous) phase must absorb strongly onto the surface of the oil droplets. Suitable colloid forming materials include one or more of polyalkylates, methyl cellulose, polyvinyl alcohol, polyacrylamide, poly(methylvinyl ether/maleic anhydride), graft copolymers of polyvinyl alcohol and methylvinyl ether/maleic acid (hydrolyzed methylvinyl ether/maleic anhydride; see U.S. Patent 4,448,929, which is hereby incorporated by reference herein), and alkali metal or alkaline earth metal lignosulfonates. Preferably, however, the protective colloid is selected from alkali metal and alkaline earth metal lignosulfonates, most preferably sodium lignosulfonates. Especially preferred colloids also contain polyvinyl alcohol.

There must be sufficient colloid present to afford complete coverage of the surfaces of all the droplets of the organic liquid. The amount of protective colloid employed will depend on various factors, such as molecular weight, compatibility, etc. The protective colloid can be added to the aqueous phase prior to the addition of the organic phase, or can be added to the overall system after the addition of the organic phase or the dispersion of it. The protective colloid is generally present in the aqueous phase in an amount of from about 0.1 to about 10.0 percent by weight.

Any surfactant used in the aqueous phase must not displace the protective colloid from the surface of the droplets of organic liquid.

If the water-immiscible liquid is a thiocarbamate or a haloacetanilide herbicide, then depending on the intended application or use of this microencapsulated product, the compositions of this invention may also include a herbicide safener or antidote.

Safeners or antidotes, when included, will usually be contained in the organic or water-immiscible phase.

The preferred average particle size of the droplets of the water-immiscible liquid containing a biologically active solid in 1-200 microns, preferably 1-30 microns and more preferably 3-20 microns. Particle size can be adjusted according to the end use of the microcapsules by adjusting stirring speed and time, and by the choice of surfactants and the amount of surfactants employed.

In order to obtain the microcapsules, the organic liquid and/or the water must contain one or more materials which can react to form a polymer at the interface between the organic liquid and the water.

In the process described in U.S. Patent 4,285,720, polyisocyanates are dissolved in the organic phase (i.e., at Step 2 in the above procedure) and polymerization takes place by hydrolysis of the prepolymers at the water/organic liquid interface to form amines which, in turn, react with unhydrolyzed monomers to form the polyurea microcapsule wall. A single compound or a mixture of two or more polyisocyanates may be used. Mixtures are preferred. Of the polyisocyanates, polymethylene polyphenylisocyanate (PAPI), and isomeric mixtures of toluene diisocyanate (TDI) are preferred. Particularly preferred are mixtures of polymethylene polyphenylisocyanate with isomeric mixtures of toluene diisocyanate, in a weight ratio of PAPI:TDI of from about 1:30 to about 4:1, especially 1:10 to 1:1.

The amount of the organic polyisocyanate used in the process will determine the wall content of the microcapsules

In general, the microcapsule wall will comprise from about 2.0 to about 75.0 percent by weight of the microcapsule. Most preferably the wall will comprise from about 4 to about 15% by weight, of the microcapsule.

The dispersion is maintained in a temperature range of from about 20°C to about 90°C preferably 40°- 60°C during which the condensation reaction takes place to form the polyurea, at the interfaces between the droplets of the organic phase and the aqueous phase.

A thiocarbamate or a haloacetanilide herbicide may be used as a solvent for the polyisocyanates. Alternatively, solvents such as xylene may be used (see Canadian Patent 1,094,402).

Another suitable system for forming microcapsules is described in U.S. 4,956,129, in which the polymer is formed from an etherified urea-formaldehyde prepolymer in which 50-98% of the methylol groups have been etherified with a C₄-C₁₀ alcohol. Self-condensation of the prepolymer takes place under the action of heat at low pH, for example at pH 0-4 at 20-100°C.

To form the microcapsules, the temperature of the two-phase mixture is raised to a value of from about 20°C to about 90°C, preferably from about 40°C to about 90°C, most preferably from about 40°C to about 60°C. Depending on the system, the pH value may be adjusted to an appropriate level.

The following are examples of preparations of compositions of this invention.

GENERAL PROCEDURE

In the first two examples which follow, the compositions were prepared by the following general procedure:

The organic phase was added to the aqueous phase, and an oil-in-water emulsion was formed by means of a high shear stirrer. The average particle size was in the range of 11.0 ± 2 microns. While mild agitation was maintained, the temperature of the batch was raised to 50°C over a period of 30 minutes, and held at 50°C for 3 hours. The resulting microcapsule suspension was then allowed to cool to room temperature. The additional ingredients were then added and the pH was then adjusted to 11.0 with 50% caustic.

EXAMPLE I 14473-27-1

A composition was prepared using the general procedure described above with the following ingredients.

EP 0 730 406 B1

Component	Weight, g.	Weight %
ORGANIC PHASE		
Atrazine (technical grade)	65.0	16.58
Acetochlor (technical grade)	100.0	25.51
N,N-diallyldichloroacetamide	17.0	4.33
Hypermer LP5	9.0	2.30
Hypermer LP1	4.0	1.02
Polymethylene polyphenylisocyanate	2.0	0.51
Toluene diisocyanate	9.0	2.29
AQUEOUS PHASE		
Reax 100M (sodium salt of lignosulfonic acid, 40% solution in water)	18.0	4.59
Gelvitol 40/10 (PVA, 20% solution in water)	18.0	4.59
Tergitol NP7 (20% solution in water)	4.0	1.02
Tergitol NP40 (70% solution in water)	1.0	0.26
Water	138.8	35.15
ADDITIONAL INGREDIENTS		
Attapulgate (attagel 40) ¹	3.8	0.98
Xanthan gum (Kelzan) ¹	0.3	0.07
Sodium carbonate ²	2.7	0.70
Proxel GXL ³	0.4	0.10
TOTAL	<u>393.0</u>	<u>100.00</u>
The resulting microencapsulated product had an average particle diameter of 10.0 microns.		

¹ = suspending agent

² = buffering agent

³ = biocide

EP 0 730 406 B1

EXAMPLE II 14585-26 A composition was prepared using the general procedure described above with the following ingredients.

Component	Weight, g.	Weight %
ORGANIC PHASE		
2-(2-nitro-4-methanesulfonylbenzoyl)-1,3-cyclohexanedione	50.0	12.50
Solvesso 200	115.0	28.75
Hypermer LP6 (40% solution in hydrocarbons)	32.0	8.00
Polymethylene polyphenylisocyanate	8.0	2.00
Toluene diisocyanate	8.0	2.00
AQUEOUS PHASE		
Reax 100M (sodium of lignosulfonic acid, 40% solution in water)	18.0	4.50
Gelvato1 40/10 (PVA, 20% solution in water)	18.0	4.50
Tergitol NP7 (20% solution in water)	4.0	1.00
Tergitol NP40 (70% solution in water)	1.0	0.25
Water	138.8	34.70
ADDITIONAL INGREDIENTS		
Attapulgate (attagel 40)	3.8	0.95
Xanthan gum (Kelzan)	0.3	0.07
Sodium carbonate	2.7	0.68
Proxel GXL	0.4	0.10
TOTAL	400.00	100.00

The resulting microencapsulated product had an average particle diameter of 12.5 microns. In each Example the final product of the process was analyzed by microscopy and polarography. The results showed that the suspension of biologically active solid was successfully microencapsulated and the aqueous phase was substantially free of the solid.

Claims

1. A microcapsule containing a solid biologically active compound selected from the group comprising pharmaceuticals and agrochemicals suspended in an organic liquid containing a dispersant which is active only at the solid/organic liquid interface and does not act as an emulsifying agent.
2. A microcapsule according to claim 1 wherein the liquid is a water-immiscible liquid.
3. A microcapsule according to claim 1 or 2 wherein the biologically active compound is an agrochemical.
4. A microcapsule according to any of claims 1-3 wherein the agrochemical is a herbicide.
5. A microcapsule according to claim 4 wherein the herbicide is atrazine.
6. A microcapsule according to any of claims 1-5 wherein the liquid is a biologically active compound selected from the group comprising pharmaceuticals and agrochemicals.
7. A microcapsule according to claim 6 wherein the liquid is a herbicide.

8. A microcapsule according to claim 7 wherein the liquid is a haloacetaldehyde or a thiocarbamate.
9. A microcapsule according to claim 8 wherein the liquid herbicide is acetochlor.
- 5 10. A microcapsule according to any of claims 7-9 wherein a herbicide safener is also present in the microcapsule.
11. A microcapsule according to any of claims 1-10 wherein the microcapsule is formed by an interfacial polymerization reaction.
- 10 12. A microcapsule according to any of claims 1-11 in which a polyurea capsule is formed from isocyanate monomers.
13. A microcapsule according to claim 12 in which the isocyanate monomer is a mixture of polymethylene polyphenylisocyanate and an isomeric mixture of toluene diisocyanate.
- 15 14. A microcapsule according to claim 1 containing from about 0.1 to about 55 weight percent of biologically active compounds.
15. A microcapsule according to claim 1 in which the capsule is formed from an etherified urea-formaldehyde prepolymer.
- 20 16. A microcapsule according to claim 15 in which the urea-formaldehyde polymer is produced from an etherified urea-formaldehyde prepolymer in which from about 50% to about 98% of the methylol groups of the said prepolymer have been etherified with a C₄-C₁₀ alcohol.
- 25 17. A microcapsule according to any of claims 12-16 in which the polymer comprises from about 4 to about 15% by weight of the capsule.
18. A process for preparing microcapsules containing a solid, biologically active compound selected from the group comprising pharmaceuticals and agrochemicals suspended in liquid containing a dispersant active only at the solid/organic liquid interface and which does not act as an emulsifying agent which process comprises:
30
a) preparing a suspension of said compound in an organic liquid which is immiscible with water and which contains a dispersant active only at the solid/organic liquid interface and which does not act as an emulsifying agent by either:
35
i) producing a powder of said compound with a particle size of 0.01-50 microns and suspending said powder in said organic liquid, or
ii) media milling said compound to a particle size of 0.01-50 microns and suspending said compound in
40 said organic liquid;
b) introducing said suspension into water containing a protective colloid and optionally a surfactant capable of maintaining the organic liquid as droplets in the water without extracting the solid from the organic liquid into the water; the organic liquid and/or the water containing in solution one or more monomers or prepolymers
45 which can react to form a polymer at the interface of the organic liquid and water;
c) mixing the suspension of organic liquid in the aqueous phase under high shear to form an oil-in-water emulsion; and
d) adjusting as necessary the temperature and/or pH of the oil-in-water emulsion such that a polymerization reaction takes place to form the microcapsules.
50
19. A process according to claim 18 wherein the particle size of the biologically active solid is 1-10 microns.
20. A process according to claim 18 or 19 wherein the particle size of the droplets of organic liquid after dispersion in
55 the water is 1-30 microns.
21. A process according to any of claims 18-20 in which the protective colloid is an alkaline metal or alkaline earth

metal lignosulfonate and optionally also contains polyvinyl alcohol.

22. A process according to any of claims 18-21 in which the surfactant in the aqueous phase has an HLB value of 12-16.
23. A process according to any claims 18-22 wherein the prepolymer is an organic polyisocyanate dissolved in the organic liquid which when heated forms a polyurea by hydrolysis of an isocyanate to an amine which in turn reacts with another isocyanate to form the polyurea.
24. A process according to claim 23 in which the polyisocyanate is a mixture of polymethylene polyphenylisocyanate and an isomeric mixture of toluene diisocyanate.
25. A process according to any of claims 18-24 wherein the prepolymer is an etherified urea-formaldehyde prepolymer in which about 50-98% of the methylol groups have been etherified with a C₄-C₁₀ alcohol, and which forms a solid polymer at pH 0-4 at 20-100°C.

Patentansprüche

1. Mikrokapsel, die eine feste biologisch aktive Verbindung, ausgewählt aus Arzneimitteln und Agrochemikalien, suspendiert in einer organischen Flüssigkeit enthält, die ein Dispergiermittel enthält, das nur an der Grenzfläche Feststoff/organische Flüssigkeit aktiv ist und nicht als Emulgiermittel dient.
2. Mikrokapsel nach Anspruch 1, in der die Flüssigkeit eine mit Wasser nicht mischbare Flüssigkeit ist.
3. Mikrokapsel nach Anspruch 1 oder 2, in der die biologisch aktive Verbindung eine Agrochemikalie ist.
4. Mikrokapsel nach einem der Ansprüche 1 - 3, in der die Agrochemikalie ein Herbizid ist.
5. Mikrokapsel nach Anspruch 4, in der das Herbizid Atrazin ist.
6. Mikrokapsel nach einem der Ansprüche 1 - 5, in der die Flüssigkeit eine biologisch aktive Verbindung, ausgewählt aus Arzneimitteln und Agrochemikalien, ist.
7. Mikrokapsel nach Anspruch 6, in der die Flüssigkeit ein Herbizid ist.
8. Mikrokapsel nach Anspruch 7, in der die Flüssigkeit ein Halogenacetanilid oder ein Thiocarbamat ist.
9. Mikrokapsel nach Anspruch 8, in der das flüssige Herbizid Acetochlor ist.
10. Mikrokapsel nach einem der Ansprüche 7 - 9, in der ein Herbizidsicherungsmittel ebenfalls in der Mikrokapsel vorhanden ist.
11. Mikrokapsel nach einem der Ansprüche 1 - 10, in der die Mikrokapsel durch eine Grenzflächenpolymerisationsreaktion gebildet wird.
12. Mikrokapsel nach einem der Ansprüche 1 - 11, in der eine Polyharnstoffkapsel aus Isocyanatmonomeren gebildet wird.
13. Mikrokapsel nach Anspruch 12, in der das Isocyanatmonomer ein Gemisch aus Polymethylenpolyphenylisocyanat und einem isomeren Gemisch von Toluoldiisocyanat ist.
14. Mikrokapsel nach Anspruch 1, die etwa 0.1 bis etwa 55 Gew.-% der biologisch aktiven Verbindungen enthält.
15. Mikrokapsel nach Anspruch 1, in der die Kapsel aus einem verethereten Harnstoff-Formaldehyd-Prepolymer gebildet wird.
16. Mikrokapsel nach Anspruch 15, in der das Harnstoff-Formaldehyd-Polymer aus einem verethereten Harnstoff-Formaldehyd-Prepolymer gebildet wird, in dem etwa 50 % bis etwa 98 % der Methylolgruppen des Prepolymers mit

einem C₄-C₁₀-Alkohol verethert wurden.

17. Mikrokapsel nach einem der Ansprüche 12 - 16, in der das Polymer etwa 4 bis etwa 15 Gew.-% der Kapsel umfaßt.
- 5 18. Verfahren zur Herstellung von Mikrokapseln, die eine feste biologisch aktive Verbindung, ausgewählt aus Arzneimitteln und Agrochemikalien, suspendiert in einer Flüssigkeit enthalten, die ein Dispergiermittel enthält, das nur an der Grenzfläche Feststoff/organische Flüssigkeit aktiv ist und nicht als Emulgiermittel dient, wobei das Verfahren umfaßt:
 - 10 a) Herstellen einer Suspension der Verbindung in einer organischen Flüssigkeit, die mit Wasser nicht mischbar ist und ein nur an der Grenzfläche Feststoff/organische Flüssigkeit wirksames Dispergiermittel enthält, das nicht als Emulgiermittel dient, durch entweder:
 - 15 i) Herstellen eines Pulvers der Verbindung mit einer Teilchengröße von 0.01 - 50 Mikron und Suspendieren des Pulvers in der organischen Flüssigkeit oder
 - ii) Mahlen der Verbindung mit einem Hilfsmittel auf eine Teilchengröße von 0.01 - 50 Mikron und Suspendieren der Verbindung in der organischen Flüssigkeit;
 - 20 b) Einbringen der Suspension in Wasser, das ein Schutzkolloid und gegebenenfalls ein grenzflächenaktives Mittel enthält, das dazu fähig ist, die organische Flüssigkeit als Tröpfchen im Wasser zu halten, ohne den Feststoff aus der organischen Flüssigkeit in das Wasser zu extrahieren; wobei die organische Flüssigkeit und/oder das Wasser in Lösung ein oder mehrere Monomere oder Prepolymere enthalten, die reagieren können, wobei an der Grenzfläche der organischen Flüssigkeit und Wasser ein Polymer gebildet wird;
 - 25 c) Mischen der Suspension der organischen Flüssigkeit in der wäßrigen Phase unter hoher Scherung, wobei eine Öl-in-Wasser-Emulsion gebildet wird; und
 - d) Einstellen der Temperatur und/oder des pH-Werts der Öl-in-Wasser-Emulsion, falls erforderlich derart, daß eine Polymerisationsreaktion stattfindet, wobei die Mikrokapseln gebildet werden.
- 30 19. Verfahren nach Anspruch 18, wobei die Teilchengröße des biologisch aktiven Feststoffs 1 - 10 Mikron beträgt.
20. Verfahren nach Anspruch 18 oder 19, wobei die Teilchengröße der Tröpfchen der organischen Flüssigkeit nach Dispersion im Wasser 1 - 30 Mikron beträgt.
- 35 21. Verfahren nach einem der Ansprüche 18 - 20, wobei das Schutzkolloid ein Alkalimetall- oder Erdalkalimetallignosulfonat ist und gegebenenfalls auch Polyvinylalkohol enthält.
22. Verfahren nach einem der Ansprüche 18 - 21, wobei das grenzflächenaktive Mittel in der wäßrigen Phase einen HLB-Wert von 12 - 16 aufweist.
- 40 23. Verfahren nach einem der Ansprüche 18 - 22, wobei das Prepolymer ein organisches Polyisocyanat gelöst in der organischen Flüssigkeit ist, das beim Erhitzen durch Hydrolyse eines Isocyanats zu einem Amin einen Polyharnstoff bildet, wobei das Amin wiederum mit einem anderen Isocyanat reagiert, wobei der Polyharnstoff gebildet wird.
- 45 24. Verfahren nach Anspruch 23, wobei das Polyisocyanat ein Gemisch von Polymethylenpolyphenylisocyanat und ein isomeres Gemisch von Toluoldiisocyanat ist.
25. Verfahren nach einem der Ansprüche 18 - 24, wobei das Prepolymer ein verethertes Harnstoff-Formaldehyd-Prepolymer ist, in dem etwa 50 - 98 % der Methylolgruppen mit einem C₄-C₁₀-Alkohol verethert wurden, und das ein festes Polymer bei einem pH-Wert von 0 - 4 bei 20 - 100°C bildet.
- 50

Revendications

- 55 1. Microcapsule contenant un composé biologiquement actif solide choisi dans le groupe comprenant les produits pharmaceutiques et les produits agrochimiques en suspension dans un liquide organique contenant un dispersant qui est actif seulement à l'interface solide/liquide organique et qui n'agit pas comme un agent émulsifiant.
2. Microcapsule selon la revendication 1 dans laquelle le liquide est un liquide immiscible à l'eau.

3. Microcapsule selon la revendication 1 ou 2 dans laquelle le composé biologiquement actif est un produit agrochimique.
- 5 4. Microcapsule selon l'une quelconque des revendications 1 à 3 dans laquelle le produit agrochimique est un herbicide.
5. Microcapsule selon la revendication 4 dans laquelle l'herbicide est l'atrazine.
- 10 6. Microcapsule selon l'une quelconque des revendications 1 à 5 dans laquelle le liquide est un composé biologiquement actif choisi dans le groupe comprenant les produits pharmaceutiques et les produits agrochimiques.
7. Microcapsule selon la revendication 6 dans laquelle le liquide est un herbicide.
8. Microcapsule selon la revendication 7 dans laquelle le liquide est un halogénoacétanilide ou un thiocarbamate.
- 15 9. Microcapsule selon la revendication 8 dans laquelle l'herbicide liquide est l'acétochlore.
10. Microcapsule selon l'une quelconque des revendications 7 à 9 dans laquelle un agent d'inocuité pour herbicides est présent aussi dans la microcapsule.
- 20 11. Microcapsule selon l'une quelconque des revendications 1 à 10 dans laquelle la microcapsule est formée par une réaction de polymérisation interfaciale.
12. Microcapsule selon l'une quelconque des revendications 1 à 11 dans laquelle une capsule de polyurée est formée à partir de monomères isocyanates.
- 25 13. Microcapsule selon la revendication 12 dans laquelle le monomère isocyanate est un mélange de polyméthylène-polyphénylisocyanate et d'un mélange d'isomères de toluènediisocyanate.
- 30 14. Microcapsule selon la revendication 1 contenant d'environ 0,1 à environ 55% en masse de composés biologiquement actifs.
15. Microcapsule selon la revendication 1 dans laquelle la capsule est formée à partir d'un prépolymère urée-formaldéhyde étherifié.
- 35 16. Microcapsule selon la revendication 15 dans laquelle le polymère urée-formaldéhyde est produit à partir d'un prépolymère urée-formaldéhyde étherifié dans lequel d'environ 50% à environ 98% des groupes méthylols dudit prépolymère ont été étherifiés avec un alcool en C₄-C₁₀.
- 40 17. Microcapsule selon l'une quelconque des revendications 12 à 16 dans laquelle le polymère constitue d'environ 4 à environ 15% en masse de la capsule.
- 45 18. Procédé de préparation de microcapsules contenant un composé biologiquement actif solide choisi dans le groupe comprenant les produits pharmaceutiques et les produits agrochimiques en suspension dans un liquide contenant un dispersant actif seulement à l'interface solide/liquide organique et qui n'agit pas comme un agent émulsifiant, lequel procédé comprend :
 - a) la préparation d'une suspension dudit composé dans un liquide organique qui est immiscible à l'eau et qui contient un dispersant actif seulement à l'interface solide/liquide organique et qui n'agit pas comme un agent émulsifiant par :
 - 50 i) production d'une poudre dudit composé ayant une taille de particule de 0,01 - 50 µm et mise en suspension de ladite poudre dans ledit liquide organique, ou
 - ii) broyage dudit composé avec des milieux de broyage jusqu'à une taille de particule de 0,01-50 µm et mise en suspension dudit composé dans ledit liquide organique;
 - 55 b) introduction de ladite suspension dans de l'eau contenant un colloïde protecteur et éventuellement un tensioactif capable de maintenir le liquide organique sous forme de gouttelettes dans l'eau sans extraire le solide

du liquide organique dans l'eau, le liquide organique et/ou l'eau contenant en solution un ou plusieurs monomères ou prépolymères qui peuvent réagir pour former un polymère à l'interface du liquide organique et de l'eau;

c) mélange de la suspension de liquide organique dans la phase aqueuse sous cisaillement élevé pour former une émulsion huile-dans-l'eau; et

d) ajustement, selon ce qui est nécessaire, de la température et/ou du pH de l'émulsion huile-dans-l'eau de manière qu'une réaction de polymérisation ait lieu pour former les microcapsules.

19. Procédé selon la revendication 18 dans lequel la taille de particule du solide biologiquement actif est de 1 à 10 μm .

20. Procédé selon la revendication 18 ou 19 dans lequel la taille de particule des gouttelettes de liquide organique après la dispersion dans l'eau est de 1 à 30 μm .

21. Procédé selon l'une quelconque des revendications 18 à 20 dans lequel le colloïde protecteur est un lignosulfonate alcalin ou alcalino-terreux et contient éventuellement aussi du poly(alcool vinylique).

22. Procédé selon l'une quelconque des revendications 18 à 21 dans lequel le tensioactif dans la phase aqueuse a une valeur HLB de 12 à 16.

23. Procédé selon l'une quelconque des revendications 18 à 22 dans lequel le prépolymère est un polyisocyanate organique dissous dans le liquide organique qui, lorsqu'il est chauffé, forme une polyurée par hydrolyse d'un isocyanate en une amine qui, à son tour, réagit avec un autre isocyanate pour former la polyurée.

24. Procédé selon la revendication 23 dans lequel le polyisocyanate est un mélange de polyméthylènepolyphénylisocyanate et d'un mélange d'isomères de toluènediisocyanate.

25. Procédé selon l'une quelconque des revendications 18 à 24 dans lequel le prépolymère est un prépolymère urée-formaldéhyde éthérifié dans lequel environ 50 à 98% des groupes méthyliols ont été éthérifiés avec un alcool en $\text{C}_4\text{-C}_{10}$, et qui forme un polymère solide à un pH de 0 à 4 à 20-100°C.